What is an ANA Multiplex?
An ANA multiplex is an automated laboratory platform that simultaneously detects multiple specific antinuclear antibodies (and related autoantibodies) in a single test, serving as an alternative or complement to traditional indirect immunofluorescence (IIF) testing on HEp-2 cells 1.
Technical Overview
ANA multiplex assays represent a technological evolution from the traditional two-step diagnostic process. These platforms include:
- Multiplex bead-based immunoassays (MBA) - such as BioPlex 2200, which uses fluorescent microspheres
- Line immunoassays (LIA) - such as EuroLine ANA Profile
- Fluorescent enzyme immunoassays
- Chemiluminescence immunoassays
- Addressable laser bead immunoassays
The key advantage is that these methods can detect specific autoantibodies (anti-dsDNA, anti-Sm, anti-SSA/Ro, anti-SSB/La, anti-RNP, anti-Scl-70, anti-Jo-1, anti-centromere, anti-histone) simultaneously in one run, rather than requiring sequential testing after an initial positive ANA screen 1.
Clinical Performance Considerations
Strengths of Multiplex Assays:
- Higher specificity than traditional IIF (83.8% for MBA vs 67.6% for HEp-2 IIF) 2
- Automated and high-throughput - ideal for busy laboratories 1
- Objective quantitative results - reduces inter-observer variability
- Better recognition sensitivity for certain diseases like SLE and systemic sclerosis 1
Critical Limitations:
- Lower sensitivity than HEp-2 IIF (79.0% for MBA vs 86.5% for IIF) 2
- Limited antigen repertoire - only tests for pre-selected antigens, potentially missing rare or novel antibodies
- Cannot detect staining patterns - loses the diagnostic information from nuclear, cytoplasmic, and mitotic patterns visible on IIF 1
- Significant false-negative rate - one large real-world study showed only 29.1% sensitivity with 8.4% false negatives 3
Important Clinical Pitfalls
The most critical caveat: multiplex assays should NOT be used as the sole primary screening method for systemic autoimmune rheumatic diseases (SARDs) 1, 3. The international consensus guidelines emphasize that HEp-2 IIF remains the reference standard for ANA screening 1.
When Multiplex Results Disagree with IIF:
If a patient is IIF positive but multiplex negative (ANA IIF+/multiplex-):
- This occurs in approximately 2.1% of cases 4
- These patients should be screened with an alternative solid-phase assay (line immunoassay or ELISA) 4
- Many of these patients have genuine SARDs, particularly systemic sclerosis and SLE 4
- Some will convert to negative on both tests after 2 years, especially those with rheumatoid arthritis or polymyalgia 4
Anti-dsDNA Discrepancies:
Multiplex assays show significant variability in anti-dsDNA detection - MBA demonstrates much higher sensitivity (58.1%) compared to LIA (19.8%) for SLE diagnosis 2. If using LIA platforms, additional anti-dsDNA testing by Farr assay or ELISA is recommended for SLE evaluation 2, 5.
Recommended Testing Algorithm
Based on the international guidelines 1:
- Primary screening: HEp-2 IIF at 1:160 dilution (or locally validated cut-off)
- If IIF positive: Reflex to multiplex assay for specific antibody identification
- If multiplex negative but IIF positive: Consider alternative solid-phase assay
- Report both methods separately - never report multiplex results as simply "ANA test" without specifying the platform 1
Laboratory Reporting Standards
Each method used must be clearly specified in the laboratory report 1. Results from IIF (including titre and pattern) and multiplex platforms should be reported separately, as they have different test characteristics and cannot be directly compared 1. This prevents clinicians from erroneously applying IIF performance characteristics to multiplex results.
The multiplex technology offers efficiency and objectivity but cannot replace the comprehensive screening capability of HEp-2 IIF, particularly for detecting rare antibodies or pattern-specific diagnoses that guide clinical decision-making 1.